Anti-tumour necrosis factor (TNF) alpha treatment of rheumatoid arthritis (infliximab) selectively down regulates the production of interleukin (IL) 18 but not of IL12 and IL13.

@article{Pittoni2002AntitumourNF,
  title={Anti-tumour necrosis factor (TNF) alpha treatment of rheumatoid arthritis (infliximab) selectively down regulates the production of interleukin (IL) 18 but not of IL12 and IL13.},
  author={Valerio Pittoni and Michele Bombardieri and Francesca Romana Spinelli and Rossana Scrivo and Cristiano Alessandri and Fabrizio Conti and Antonio Spadaro and Guido Valesini},
  journal={Annals of the rheumatic diseases},
  year={2002},
  volume={61 8},
  pages={723-5}
}
OBJECTIVE To measure interleukin (IL)18 serum concentrations in patients with rheumatoid arthritis (RA) undergoing infliximab treatment (tumour necrosis factor (TNF) alpha blockade) and to evaluate the concomitant modification of IL12 and IL13 serum concentrations, two cytokines belonging to the Th1 and Th2 profile respectively and biologically related to IL18. METHODS Ten patients with RA not responding to disease modifying antirheumatic drugs (DMARDs) received intravenous infliximab at a… CONTINUE READING
28 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 28 extracted citations

Similar Papers

Loading similar papers…